Klinischer Newsletter
Für regelmmäßige Updates zu unseren neusten Studien:
Unsere Forschungs- und Entwicklungsteams sind weltweit im Einsatz und generieren Synergien aus unserem Expertenwissen und verwandten Fachdisziplinen. Wir stehen im internationalen Austausch mit unabhängigen Fachinstitutionen, Key Opinion Leadern und Multiplikatoren, um so Kooperations- und Wissensmanagement auf höchstem Niveau gewährleisten zu können. Im Rahmen dessen führen wir umfangreiche Forschungen durch, die kontinuierlich auf Kongressen in Form von Postern oder freien Vorträgen unserer Kooperationspartner sowie in Symposien und Workshops präsentiert und in namhaften wissenschaftlichen Fachzeitschriften veröffentlicht werden. Die größtenteils von unabhängigen Gutachtern bewerteten, evidenzbasierten Fachpublikationen, stellen wir Ihnen in dieser Datenbank zur Verfügung:
Venous ulceration, a relative common manifestation of chronic venous insufficiency and venous hypertension, is often difficult to treat. Successful treatment begins with the management of the underlying pathology and wound bed preparation. This article reports the authors' experience with a novel wound dressing produced from microbial cellulose synthesized by an acid- producing bacterium, Acetobacter xylinium. Twenty-four patients with chronic venous insufficiency and lower-leg ulceration were treated with either biocellulose wound dressing (BWD) plus a two- layer compression bandage or standard care. Standard care consisted of a nonadherent primary wound dressing plus a two-layer compression bandage. Evaluations were performed weekly to measure wound pain, nonviable tissue reduction, degree of wound granulation, and wound healing (reduction in wound size and surface area). BWD was significantly more effective than standard care for autolytic debridement (reduction in the amount of nonviable tissue [p=0.0094]). The mean number of days to >75-percent granulation was 43 days for the BWD treated group and 71 for the standard care group. Mean percent reduction in wound area was also greater for the BWD treated group at Week 6 (39% vs. 19%) and at Week 12 (74% vs. 49%). When compared to patients treated with standard care, the group treated with BWD reported less wound pain at each evaluation point. Significant differences in wound pain scores between the two treatments were noted at Week 3, 6 (p=0.039), and 8 (p=0.043).
OBJECTIVE
This study set out to investigate the pain control and absorptive properties of a new sheet hydrogel dressing (ActiFormCool, Activa).
METHOD
This was a simple evaluation involving 20 wounds. Compression was used when appropriate, although each patient receiving compression had used short-stretch bandages before entering the study.
RESULTS
Pain was reduced from an average of 8.65 to an average of 3.75, where 10 represents the worst pain possible and one represents no pain. Exudate reduction was assessed by the number of dressing changes required each week. The dressing-change rate reduced from an average of 2.8 times weekly to an average of 1.3 times weekly. Skin condition improved in all three cases in which the surrounding skin had been a problem before the study. Over a four-week period, two wounds healed, four healed by 90% and two by 80%, with an overall average healing rate of 46%.
CONCLUSION
ActiFormCool provides an optimum wound-healing environment, reduces pain and absorbs fluid, making it an excellent alternative to loose hydrogels.
Actico compression bandage system (Activa Healthcare) completes the prevention and treatment regime of venous leg ulcer management. Actico gives the patient comfort by being a simple two-layer compression bandage system that is also effective and which stays in place because of its cohesive nature. This product focus looks at the impact of venous leg ulcers, the use of compression and focuses on short-stretch bandages and the Actico bandage system.